Psilocybin - Definium Therapeutics/The University Hospital of Basel
Latest Information Update: 22 Jan 2026
At a glance
- Originator The University Hospital of Basel
- Developer Definium Therapeutics; The University Hospital of Basel
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Ethylamines; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phosphates; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Psychotic disorders